The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Official Title: A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
Study ID: NCT05678270
Brief Summary: This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Provincial Hospital, Hefei, Anhui, China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Beijing Youan Hosptital,Capital Medical University, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
Beijing Hospital, Beijing, Beijing, China
Fujian Cancer Hospital, Fujian, Fujian, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Mengchao hepatobiliary Hospital of FuJian Medical university, FuZhou, Fujian, China
Foshan First People's Hospital, Foshan, Guangdong, China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
First Affiliated Hospital of Zhengzhou University., Zhengzhou, Henan, China
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Human Provincial People's Hospital, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
The Third Xiangya Hospital of Central South Uninversity, Changsha, Hunan, China
Changzhou Tumor Hospital, Changzhou, Jiangsu, China
Jiangyin Renmin Hospital, Jiangyin, Jiangsu, China
The Affiliated Hospital of Nanjing University Meidical School, Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Xuzhou Central Hospital, Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Jiangxi Cancer Hospital, Nanchang, Nanchang, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Tangdu Hospital of the Fourth Military Medical University, Xi'an, Shaanxi, China
Qilu Hospital, Jinan, Shandong, China
Jinan Central Hospital, Jinan, Shandong, China
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
ZhongShan Hospital, Shanghai, Shanghai, China
The Third Affiliated Hospital of Naval Medical University, Shanghai, Shanghai, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Shulan(Hangzhou) Hospital, Hangzhou, Zhejiang, China
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Name: Jin Li
Affiliation: Shanghai East Hospital
Role: PRINCIPAL_INVESTIGATOR